|
|
|
|
 |
|  =Subscribers Only |
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |
|
 JUNE 11, 2004 The Bloom Is Off the ASCO Rose The annual cancer confab is over, and once again, so is investors' euphoria over possible breakthroughs MAY 20, 2004 Statins in Aisle 7? Following Britain's lead, the FDA could soon approve the popular cholesterol-lowering medicines as over-the-counter remedies MAY 5, 2004 A Cancer Drug Under a Cloud Several troubling but inconclusive studies suggest that EPO, a huge earner for Amgen and J&J, might actually lower survival rates APRIL 29, 2004 Bigger Than Depression? Once associated mainly with hyper kids, attention deficit disorder is now widely diagnosed in adults. But drugs aren't the only answer APRIL 8, 2004 Has Obesity Met Its Match? The French pharma Sanofi is getting positive results so far with a drug that suppresses appetite. And it may have cardiac benefits, too MARCH 26, 2004 Angiotech's Drug-Coated Pipeline The Canadian outfit had its first hit with Taxus stents, licensed to Boston Scientific. Now, it's working to build on that success MARCH 15, 2004 A Risky Bet on Antibiotics? Small companies are licensing promising products rather than developing them from scratch. That may do little for profits and less for science MARCH 5, 2004 Acambis' Springboard: Smallpox The little biotech has done well supplying a vaccine to the U.S. CEO Gordon Cameron discusses how it plans to sustain its success FEBRUARY 25, 2004 Flu Vaccines for Everyone? If Uncle Sam made shots universal, a stabilized vaccine industry might be ready for the killer virus doctors have long feared FEBRUARY 20, 2004 Feds to Biotech: No More Fibbing! A little-noted change in drug-approval procedures is a step toward avoiding more ImClone-style stock scandals FEBRUARY 10, 2004 An Upstart's Take on Biotech's Ills Dan Adams of Protein Sciences doesn't mince words. His industry's biggest flaw, he says, is that it's horrendously managed by egomaniacs FEBRUARY 6, 2004 "Good" Cholesterol: Great for Kos The tiny drugmaker has been on a tear lately, thanks to its HDL-boosting drugs. CEO Adrian Adams talks about some challenges ahead JANUARY 9, 2004 Genzyme: Beyond "Orphan" Diseases Though the biotech made its name developing drugs for extremely limited markets, CEO Henri Termeer is now targeting broader areas JANUARY 5, 2004 What's Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D, mergers, and the FDA's changing role DECEMBER 29, 2003 A Happy Pill for Some Biotechs Analysts predict 2003's rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers DECEMBER 4, 2003 TB: Battling an Old Foe's Resurgence Foundations and drug companies are finding fresh ways to fight tuberculosis, a deadly disease given new life by the AIDS epidemic NOVEMBER 13, 2003 Faster Pulses for Biotech Investors Any slowdown will be temporary, says VC Nick Galakatos, who believes 2004's promising products will be a catalyst for the sector NOVEMBER 7, 2003 The New World of Tailored Treatments For Big Pharma, gene-based therapies that can be personalized to individual patients are a major challenge -- and a bigger opportunity OCTOBER 24, 2003 Seeking a Prescription for Biogenerics No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now working to change that OCTOBER 16, 2003 Cancer Drugs That Keep Survivors Going A new class of maintenance therapies with low side effects is showing promise in keeping patients from suffering relapses  View Next Page | | |
|
Copyright by The McGraw-Hill Companies Inc. All rights reserved.